An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45

This publication has 12 references indexed in Scilit:

• Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
  Annals of Oncology, 2016
• Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group
  Targeted Oncology, 2015
• EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review
  Journal of Comparative Effectiveness Research, 2015
• Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
  Breast Cancer Research and Treatment, 2012
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
  The Lancet Oncology, 2011
• Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation
  Health Technology Assessment, 2007
• Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer
  Annals of Oncology, 2007
• Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
  Cancer Treatment Reviews, 2000
• Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.
  Journal of Clinical Oncology, 1997
• The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.
  Journal of Clinical Oncology, 1996